European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

personalised Diabetes Management using lOw-cost Needle-free multiple-biomarkers monitoring Device

Objectif

"""Diabetes is the #1 health challenge of the 21st century. Continuous Glucose Monitoring or CGM ($1.25B market in 2016, growing 29%/yr) is today’s cornerstone of “diabetes self-management” and the most effective solution to reduce the economic and societal burden of diabetes. But the shortcomings of current CGMs hinder their wider adoption: high cost, unsatisfactory predictability of severe events, and poor user comfort. The DiaMOND project will remove these barriers by bringing needle-free, low-cost Continuous Diabetes Monitoring to market. DiaMOND is specifically geared at extending Indigo’s current CGM with reliable severe clinical event prediction and a great user experience; demonstrating the reliability in a first-in-man trial; creating market acceptance by involving Key Opinion Leaders; and obtaining reimbursement. Indigo will be ready for a large pivotal clinical study and CE marking after completing the DiaMOND project. DiaMOND will accelerate Indigo’s CDM market access by 2-3 years."""

Appel à propositions

H2020-EIC-SMEInst-2018-2020

Voir d’autres projets de cet appel

Sous appel

H2020-SMEInst-2018-2020-2

Régime de financement

SME-2 - SME instrument phase 2

Coordinateur

INDIGO DIABETES
Contribution nette de l'UE
€ 2 493 273,13
Adresse
BOLLEBERGEN 2B/30
9052 Gent
Belgique

Voir sur la carte

PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.

Oui
Région
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 4 519 408,75